Thomas Malley Net Worth

The estimated Net Worth of Thomas Malley is at least $2.35 Million dollars as of 5 June 2024. Mr. Malley owns over 4,373 units of BeiGene Ltd stock worth over $1,979,109 and over the last 12 years he sold BGNE stock worth over $0. In addition, he makes $373,000 as Non-Executive Independent Director at BeiGene Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Malley BGNE stock SEC Form 4 insiders trading

Thomas has made over 7 trades of the BeiGene Ltd stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 4,373 units of BGNE stock worth $923,359 on 5 June 2024.

The largest trade he's ever made was buying 50,000 units of BeiGene Ltd stock on 16 June 2023 worth over $575,000. On average, Thomas trades about 3,316 units every 122 days since 2012. As of 5 June 2024 he still owns at least 9,373 units of BeiGene Ltd stock.

You can see the complete history of Mr. Malley stock trades at the bottom of the page.

Thomas Malley biography

Thomas Robert Malley serves as Non-Executive Independent Director of the Company. Mr. Malley has served as president of Mossrock Capital, LLC, a private investment firm, since May 2007. Mr. Malley worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund and also led the Janus healthcare team of analysts. From 1991 to 1998, Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley received a B.S. in Biology from Stanford University in January 1991. Mr. Malley has held directorships in the following listed companies: • Kura Oncology, Inc., a company listed on the Nasdaq, as a director since 2015; • Kiniksa Pharmaceuticals, a company listed on the Nasdaq, as a director since 2016; • OvaScience, Inc., a company listed on the Nasdaq, as a director from 2012 to 2017; • Synageva BioPharma Corp., a Company listed on the Nasdaq prior to its delisting in May 2015 in connection with the sale of the company, as a director from 2006 to 2015; • Puma Biotechnology, Inc., a company listed on the Nasdaq, as a director from 2011 to 2015; and • Cougar Biotechnology, Inc., a company listed on the Nasdaq prior to its delisting in July 2009 in connection with the sale of the company, as a director from 2007 to 2009.

What is the salary of Thomas Malley?

As the Non-Executive Independent Director of BeiGene Ltd, the total compensation of Thomas Malley at BeiGene Ltd is $373,000. There are 9 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.

How old is Thomas Malley?

Thomas Malley is 51, he's been the Non-Executive Independent Director of BeiGene Ltd since 2016. There are 12 older and 9 younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.

What's Thomas Malley's mailing address?

Thomas's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.

Insiders trading at BeiGene Ltd

Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., and Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.

What does BeiGene Ltd do?

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Complete history of Mr. Malley stock trades at BeiGene Ltd, Kura Oncology Inc, Puma Biotechnology Inc, and Kiniksa Pharmaceuticals International Plc

BeiGene Ltd executives and stock owners

BeiGene Ltd executives and other stock owners filed with the SEC include:

• John Oyler,
  Co-Founder, Executive Chairman of the Board, Chief Executive Officer
• Xiaodong Wang,
  Co-Founder, Non-Executive Director
• Dr. Xiaodong Wang Ph.D.,
  Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director
• John V. Oyler,
  Co-Founder, Exec. Chairman & CEO
• Dr. Xiaobin Wu Ph.D.,
  Pres, COO & GM of China
• Wang Lai,
  Global Head of R&D
• Dr. Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Jane Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Heng Liang,
  CFO & Chief Strategy Officer
• Thomas Malley,
  Non-Executive Independent Director
• Qingqing YI,
  Non-Executive Independent Director
• Timothy Chen,
  Non-Executive Independent Director
• Jing-Shyh Su,
  Non-Executive Independent Director
• Donald Glazer,
  Non-Executive Independent Director
• Ranjeev Krishana,
  Non-Executive Independent Director
• Michael Goller,
  Non-Executive Independent Director
• Corazon Sanders,
  Non-Executive Independent Director
• Anthony Hooper,
  Non-Executive Director
• Hing Ling Chau,
  Company Secretary
• Jane Huang,
  Chief Medical Officer, Hematology
• Xiaobin Wu,
  General Manager - China, President
• Kevin C. Mannix,
  Sr. VP of Investor Relations.
• Mi Zhou,
  Sr. Director of Investor Relations
• Julia Wang,
  CFO & Principal Accounting Officer
• Diana Lee Francis,
  VP and Global Head of Quality & Regulatory Compliance
• Scott Samuels,
  Sr. VP & Gen. Counsel
• Craig West CFA,
  Sr. Director of Investor Relations
• Michael Garvey,
  Global Head of Technical Operations
• Daniel Maller,
  VP of Fin. & Accounting
• Jianxin Yang,
  Sr. VP, Head of Clinical Dev.
• Amy C. Peterson,
  CMO, Immuno-oncology
• Ji Li,
  EVP and Gl. Head of Bus. Dev.
• Investment Management, Ltd....,
  10% owner
• Rui Rong Yuan,
  Chief Medical Officer
• Ke Tang,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Biotech Investment Ltd Cpe ...,
  
• Wendy Xiaojun Yan,
  Sr. VP, Head of Reg. Affairs
• & Co., Inc.Merck Sharp & Do...,
  
• Chan Henry Lee,
  SVP, General Counsel
• Bros. Advisors Lp14159, L.P...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Howard Liang,
  CFO & Chief Strategy Officer
• Inc Amgen,
  10% owner
• Lai Wang,
  Global Head of R&D
• Olivier Brandicourt,
  Director
• Julia Aijun Wang,
  Chief Financial Officer
• Margaret Dugan,
  Director
• Advisors, Ltd.Hillhouse Inv...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Titus B. Ball,
  Principal Accounting Officer
• Aaron Rosenberg,
  Chief Financial Officer